navigating-angles-retrospective-analysis-one-year-outcomes-gonioscopy

Navigating the Angles: A Retrospective Analysis of One-year Outcomes of Gonioscopy-assisted Transluminal Trabeculotomy in Primary Open-angle Glaucoma

This study aimed to evaluate postoperative angle changes following gonioscopy-assisted transluminal trabeculotomy (GATT) in patients with primary ...

trabeculotome-tunneling-trabeculoplasty-3t-step-step-surgical

Trabeculotome Tunneling Trabeculoplasty (3T): A Step-by-step Surgical Protocol for Primary Open-angle Glaucoma

Primary open-angle glaucoma (POAG) requires sustained intraocular pressure (IOP) reduction to delay disease progression. Traditional filtering surgeries, ...

Chengdu First People's Hospital

Chengdu Integrated TCM ' Western Medicine Hospital

The intraocular injections of anti-vascular endothelial growth factor (anti-VEGF) demonstrates significant efficacy in inhibiting the formation of ocular neovascularization in neovascular glaucoma (NVG). Ahmed glaucoma valve implantation (AGVI) is extensively employed for the management of diverse glaucoma types.

The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-analysis.

Dry eye disease (DED) is highly prevalent worldwide, leading to increased medical costs, economic burdens on families and society, and a diminished quality of life for patients. The utilization of autologous serum eye drops (ASEDs) for the treatment of DED is progressively rising.

Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials.

Faricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs) in real-world settings is crucial. This study employed the FDA Adverse Event Reporting System (FAERS) database to investigate potential safety concerns, with the aim of providing new insights for clinical practice.

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database.

Recognizing potential immune checkpoint inhibitor-associated optic neuritis: insights from the FDA adverse event reporting system.

A preservative-free intranasal formulation of varenicline (Tyrvaya) has been developed and approved in the United States for the treatment of the signs and symptoms of dry eye disease (DED). Given its growing use in the clinical treatment of DED, understanding its safety in real-world settings is essential. This study aims to further assess the safety concerns after the launch of Tyrvaya. This study analyzed all adverse events (AEs) reports from the FDA Adverse Event Reporting System database, in which Tyrvaya was identified as the primary suspected drug, starting from the fourth quarter of 2021, to evaluate its safety in clinical practice. To ensure the accuracy and reliability of the study, we employed 4 types of disproportionality analyses: the reporting odds ratio, proportional reporting ratio, multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network. Additionally, the Weibull distribution was utilized to model the risk of AEs over time. A total of 2178 patients and 5189 reports associated with Tyrvaya administration were collected. Positive signal detection of Tyrvaya at the system organ class level included respiratory, thoracic, and mediastinal disorders, product issues, and eye disorders. At the preferred term level, the AEs listed on the drug label were confirmed, including sneezing, cough, throat irritation, and instillation-site (nasal) irritation. Furthermore, several adverse reactions not listed in the medication leaflet but deemed clinically significant were identified, including blurred vision, burning sensation, upper-airway cough syndrome, nasal ulcers, dysphonia, abnormal dreams, photophobia, and eye swelling. Additionally, we identified potential adverse reactions, including headache, insomnia, and vertigo. This study identified known AEs associated with Tyrvaya and uncovered new AE signals that had not been previously reported. These findings offer clinicians additional safety insights for the use of Tyrvaya in treating DED.

ArticleTotal : 2	Year
Publication title	2026
Publication title	2026

Article	Year
The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-anal... Frontiers in medicine\| PubMed ID: 39144652	2024
Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials. Frontiers in medicine\| PubMed ID: 39346942	2024
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database. Frontiers in pharmacology\| PubMed ID: 40144657	2025
Recognizing potential immune checkpoint inhibitor-associated optic neuritis: insights from the FDA adverse event reporting system. International ophthalmology\| PubMed ID: 40853404	2025
Post-marketing safety assessment of Tyrvaya: A real-world pharmacovigilance analysis based on the FDA Adverse Event Reporting System. Medicine\| PubMed ID: 41189154	2025
A new minimally invasive glaucoma surgery namely trabeculotome tunneling trabeculoplasty for steroid-induced glaucoma: a case report. International journal of ophthalmology\| PubMed ID: 41280638	2025

Qin Qiu

Biography

JoVE Journal Publications

Other Publications